** Shares of Neuren Pharmaceuticals NEU.AX rise 11% to A$13.92, their highest since June 13
** Stock is the top gainer on the benchmark index .AXJO
** Stock on track for best day since April 14 if gains hold
** Co receives patent application approval from U.S. regulator for the use of its NNZ-2591 drug to treat Pitt Hopkins syndrome, a neurodevelopmental condition
** Says patent's expiry date will be in April 2040
** Including day's moves, stock up 11.7% YTD
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((JasmeenAraIslam.Shaikh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.